Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 22 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-5.98 Insider Own0.19% Shs Outstand55.30M Perf Week3.81%
Market Cap6.32M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float55.20M Perf Month24.92%
Income-10.77M PEG- EPS next Q- Inst Own0.40% Short Float1.19% Perf Quarter-10.63%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio0.05 Perf Half Y-97.34%
Book/sh-1.02 P/B- EPS next Y- ROA-179.36% Short Interest0.66M Perf Year-96.53%
Cash/sh0.01 P/C9.58 EPS next 5Y- ROE-329.00% 52W Range0.08 - 5.98 Perf YTD-32.61%
Dividend Est.- P/FCF- EPS past 5Y49.09% ROI- 52W High-98.09% Beta0.49
Dividend TTM- Quick Ratio0.63 Sales past 5Y0.00% Gross Margin- 52W Low41.11% ATR (14)0.02
Dividend Ex-Date- Current Ratio0.63 EPS Y/Y TTM60.42% Oper. Margin0.00% RSI (14)50.21 Volatility8.08% 13.20%
Employees17 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom2.00 Target Price14.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q88.77% Payout- Rel Volume0.16 Prev Close0.12
Sales Surprise- EPS Surprise-71.43% Sales Q/Q- EarningsFeb 14 AMC Avg Volume13.85M Price0.11
SMA20-0.29% SMA507.82% SMA200-93.63% Trades Volume2,283,733 Change-5.85%
Apr-04-24 10:38AM
Apr-03-24 09:46AM
Mar-27-24 09:00AM
Feb-14-24 04:07PM
09:00AM Loading…
Feb-12-24 09:00AM
Dec-07-23 09:00AM
Dec-05-23 09:00AM
Nov-13-23 04:10PM
Oct-31-23 08:00AM
Oct-11-23 08:00AM
Oct-02-23 08:00AM
Sep-25-23 07:30AM
Sep-21-23 09:35AM
Sep-18-23 04:25PM
08:00AM Loading…
Sep-05-23 08:00AM
Aug-17-23 05:00PM
Aug-09-23 08:16AM
Aug-08-23 07:00AM
Jul-19-23 08:00AM
Jun-30-23 11:07AM
Jun-28-23 04:15PM
Jun-16-23 08:00AM
May-19-23 08:30AM
May-11-23 08:15AM
May-09-23 07:15AM
May-08-23 08:30AM
May-01-23 08:30AM
Apr-14-23 12:00PM
Mar-15-23 08:00AM
08:30AM Loading…
Mar-10-23 08:30AM
Feb-14-23 05:00PM
Jan-30-23 08:00AM
Jan-09-23 08:30AM
Dec-15-22 08:00AM
Dec-02-22 09:47AM
Dec-01-22 08:00AM
Nov-30-22 08:00AM
Nov-28-22 08:00AM
Nov-18-22 08:00AM
Nov-11-22 08:00AM
Nov-09-22 05:20PM
Oct-19-22 08:15AM
Sep-27-22 08:15AM
Sep-08-22 07:00AM
Aug-09-22 09:00AM
Aug-03-22 08:30AM
Jun-21-22 08:00AM
Jun-15-22 09:00AM
Jun-10-22 09:00AM
Jun-03-22 09:00AM
May-27-22 09:30AM
May-17-22 07:00AM
May-13-22 08:00AM
Apr-27-22 09:00AM
Apr-26-22 07:30AM
Apr-14-22 04:05PM
Apr-12-22 11:47AM
Apr-11-22 02:30PM
Mar-22-22 08:00AM
Mar-15-22 07:00AM
Feb-14-22 06:10AM
Feb-11-22 08:15AM
Feb-04-22 07:00AM
Feb-03-22 07:00AM
Jan-25-22 07:45AM
Jan-12-22 08:00AM
Jan-05-22 08:00AM
Dec-07-21 08:00AM
Nov-30-21 08:00AM
Nov-18-21 08:00AM
Nov-17-21 04:42AM
Nov-15-21 08:15AM
Nov-11-21 08:30AM
Nov-09-21 08:00AM
Nov-03-21 11:13AM
Oct-14-21 05:00AM
Oct-11-21 08:00AM
Sep-29-21 08:00AM
Sep-28-21 01:33PM
Sep-27-21 05:04AM
Sep-24-21 08:00AM
Sep-22-21 12:30PM
Aug-17-21 08:00AM
Aug-12-21 08:00AM
Aug-06-21 10:20AM
Aug-04-21 08:00AM
Jul-09-21 06:29AM
Jul-07-21 12:56PM
Jul-01-21 01:36PM
Jun-13-21 10:20PM
Jun-07-21 08:00AM
Jun-03-21 08:00AM
Jun-02-21 08:00AM
May-26-21 12:25PM
May-14-21 08:00AM
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.